---
title: "Oncolytics Biotech swaps auditor Ernst & Young for Baker Tilly"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292111239.md"
description: "Oncolytics Biotech has switched its independent auditor from Ernst & Young to Baker Tilly US, effective July 6, 2026, due to corporate restructuring. Baker Tilly will audit fiscal 2026 pending client acceptance. Ernst & Young's prior opinions were unqualified with a going-concern note. The company reported no disagreements with the former auditor regarding accounting or audit scope."
datetime: "2026-07-08T20:24:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292111239.md)
  - [en](https://longbridge.com/en/news/292111239.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292111239.md)
---

# Oncolytics Biotech swaps auditor Ernst & Young for Baker Tilly

-   Oncolytics Biotech switched auditors, disengaging Ernst & Young on July 6, 2026, citing a corporate restructuring. \* Baker Tilly US was engaged as independent auditor for fiscal 2026, subject to completion of client acceptance procedures. \* Ernst & Young audit opinions for 2025 and 2024 were unqualified, with a going-concern explanatory paragraph. \* No reported disagreements with Ernst & Young on accounting, disclosure, or audit scope through the change date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-081797), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md)

## Related News & Research

- [Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard](https://longbridge.com/en/news/293796222.md)
- [Oncolytics reports FDA Type D meeting and rapid progress in randomized REO 033 colorectal cancer trial](https://longbridge.com/en/news/292494699.md)
- [Exelixis (EXEL) Stock Still Looks Like A Bargain On Earnings](https://longbridge.com/en/news/293850805.md)
- [Solventum’s Q2 2026 Earnings: What to Expect](https://longbridge.com/en/news/293459582.md)
- [Marshall Wace discloses net short position in Abivax](https://longbridge.com/en/news/293627978.md)